Literature DB >> 19960329

Immunohistochemical detection of tumour hypoxia.

Richard J Young1, Andreas Möller.   

Abstract

In this chapter, we describe the use of immunohistochemical methods to detect hypoxia in tumour tissue sections, utilising antibodies specific for endogenous proteins hypoxia inducible factor 1 alpha (Hif1alpha) and glucose transporter 1 (Glut-1) and the exogenous compound pimonidazole (Pim). Immunohistochemistry is routinely used both diagnostically and in research to label and identify specific cellular proteins of interest. The methods described here enable staining of hypoxic cells and tissue in formalin-fixed paraffin-embedded (FFPE) tumour tissue sections that can then be visualised either using chromogenic or fluorescence detection. All three methods can be used on human, xenograft, or mouse tumour tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19960329     DOI: 10.1007/978-1-60327-345-9_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Authors:  Claire Lhuillier; Claire Vanpouille-Box; Lorenzo Galluzzi; Silvia Chiara Formenti; Sandra Demaria
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

2.  18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.

Authors:  Edwin Chang; Hongguang Liu; Kerstin Unterschemmann; Peter Ellinghaus; Shuanglong Liu; Volker Gekeler; Zhen Cheng; Dietmar Berndorff; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-11-07       Impact factor: 12.531

3.  Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma.

Authors:  Yana G Najjar; Ashley V Menk; Cindy Sander; Uma Rao; Arivarasan Karunamurthy; Roma Bhatia; Shuyan Zhai; John M Kirkwood; Greg M Delgoffe
Journal:  JCI Insight       Date:  2019-03-07

Review 4.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

5.  Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.

Authors:  Leilei Tao; Guichun Huang; Shujing Shi; Longbang Chen
Journal:  Med Oncol       Date:  2013-11-24       Impact factor: 3.064

6.  Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.

Authors:  Dan P Zandberg; Ashley V Menk; Maria Velez; Daniel Normolle; Kristin DePeaux; Angen Liu; Robert L Ferris; Greg M Delgoffe
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

7.  Macrophage-Induced Blood Vessels Guide Schwann Cell-Mediated Regeneration of Peripheral Nerves.

Authors:  Anne-Laure Cattin; Jemima J Burden; Lucie Van Emmenis; Francesca E Mackenzie; Julian J A Hoving; Noelia Garcia Calavia; Yanping Guo; Maeve McLaughlin; Laura H Rosenberg; Victor Quereda; Denisa Jamecna; Ilaria Napoli; Simona Parrinello; Tariq Enver; Christiana Ruhrberg; Alison C Lloyd
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

8.  Emerging evidence of the physiological role of hypoxia in mammary development and lactation.

Authors:  Yong Shao; Feng-Qi Zhao
Journal:  J Anim Sci Biotechnol       Date:  2014-01-21

9.  Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

Authors:  Anna Király; Tímea Váradi; Tímea Hajdu; Ralph Rühl; Carlos M Galmarini; János Szöllősi; Peter Nagy
Journal:  Mar Drugs       Date:  2013-12-02       Impact factor: 5.118

10.  The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.

Authors:  Jaclyn Sceneay; Mira C P Liu; Anna Chen; Christina S F Wong; David D L Bowtell; Andreas Möller
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.